Document text
Principal Investigator: Leah Katzelnick
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2022
Award: $1,477
Funding agency: National Institute of Allergy and Infectious Diseases
Immunity to endemic coronaviruses and SARS-CoV-2 before and during the COVID-19 pandemic in children in Cebu, Philippines.
NIAID and University of the Philippines Manila are collaborating to study SARS-CoV-2 and endemic coronavirus seroprevalence in children in the Central Visayas Region in the Philippines. In this region, numerous variants of concern now circulate but little is known about the infection and disease risk for SARS-CoV-2. This study is part of an ongoing longitudinal cohort of children 12-17 years of age and residing in Bogo and Balamban participating in the study entitled "Effect of baseline dengue serostatus among tetravalent dengue vaccine CYD-TDV (Dengvaxia) recipients on subsequent virologically confirmed dengue in the Philippines". This cohort provides a unique opportunity to interrogate immunity induced by endemic coronaviruses prior to the start of the COVID-19 pandemic (late 2019/early 2020) and follow the same children over the course of the pandemic (2020 and 2021). We have used ELISAs and epidemiological methods to measure serum antibodies to the receptor binding domains and spike antigens of SARS-CoV-2, OC43, HKU1, 229E, and NL63.
Effect of sequential exposure on breadth of immunity to SARS-CoV-2 variants.
The rapid emergence of new SARS-CoV-2 variants challenges vaccination strategies. In collaboration with teams at the FDA and USU, we characterized the antigenic diversity among SARS-CoV-2 variants following single and multiple exposures in longitudinal infection and vaccine cohorts. We made antigenic maps for primary infection neutralization titers and showed that BA.2, BA.4/BA.5, and BA.2.12.1 are distinct from BA.1 and are more similar to the Beta/Mu/Gamma cluster. Further, we found that three doses of an mRNA COVID-19 vaccine increased neutralization recognition of BA.1 more than BA.4/BA.5 or BA.2.12.1. We used a related technique called an antibody landscape to show that Omicron BA.1/BA.1.1 post-vaccination infection (PVI) elicited more balanced neutralization of distinct variants than three doses alone, including to unexposed variants, although with a smaller gain than expected to BA.2.12.1 and BA.4/BA.5. Those with BA.1/BA1.1 infection after two or three vaccinations had similar neutralization titer magnitude and antigenic breadth. Overall, our analyses accounting for antigenic differences among variants of concern when interpreting neutralization titers aids understanding of complex patterns in humoral immunity and informs selection of future COVID-19 vaccine strains.
Preprint: Wang W, Lusvarghi S, Subramanian R, Epsi NJ, Wang R, Goguet E, Fries AC, Echegaray F, Vassell R, Coggins SA, Richard SA, Lindholm DA, Mende K, Ewers E, Larson D, Colombo RE, Colombo C, Joseph JO, Rozman J, Smith A, Lalani T, Berjohn C, Maves R, Jones M, Mody R, Huprikar N, Livezey J, Saunders D, Hollis-Perry M, Wang G, Ganesan A, Simons MP, Broder CC, Tribble D, Laing ED, Agan B, Burgess TH, Mitre E, Pollett SD*, Katzelnick LC*, Weiss CD*. Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection. bioRxiv. Posted July 06, 2022. doi: 10.1101/2022.07.05.498883. *Corresponding authors.
Terms: <0-11 years old><17 year old><17 years of age><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Accounting><Antibodies><Antigenic Diversity><Blood Serum><Booster Immunization><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 antigen><COVID-19 booster><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 immunity><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 vaccine><COVID-19 vaccine booster><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 immunity><COVID19 pandemic><COVID19 public health crisis><COVID19 vaccine><COVID19 virus><Child><Child Youth><Children (0-21)><CoV-2><CoV2><Collaborations><Complex><Coronaviridae><Coronavirus><DENV vaccine><Dengue><Dengue Vaccine><Dengue virus vaccine><Dengvaxia><Dose><ELISA><Enzyme-Linked Immunosorbent Assay><Epidemiologic Methods><Epidemiological Methods><Epidemiological Techniques><Epidemiology><Evolution><Flavivirus><Future><Group B Arbovirus><HCoV><Humoral Immunities><Immune><Immunes><Immunity><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><Immunology><Infection><Long-term cohort><Longitudinal cohort><Longterm cohort><Maps><Measures><Messenger RNA><Methods Epidemiology><Mites><NIAID><National Institute of Allergy and Infectious Disease><Pattern><Philipines><Philippines><Phillipines><Phillippines><Predisposition><Primary Infection><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antigen><SARS-CoV-2 booster><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 immunity><SARS-CoV-2 pandemic><SARS-CoV-2 vaccine><SARS-CoV-2 vaccine booster><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 antigen><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Secondary Immunization><Seroprevalences><Serum><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 immunity><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Susceptibility><Techniques><Universities><Vaccination><Vaccines><Variant><Variation><Viral Diseases><Viral Epidemiology><Virus Diseases><Wuhan coronavirus><age 17 years><antibody-based immunity><booster against COVID-19><booster against SARS-CoV-2><booster vaccination><cohort><corona virus><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019 antigen><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 immunity><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><disease risk><disorder risk><enzyme linked immunoassay><epidemiologic><epidemiological><hCoV19><human CoV><human corona virus><human coronavirus><immunity against COVID-19><immunity against COVID19><immunity against SARS-CoV-2><immunity against Severe acute respiratory syndrome coronavirus 2><immunity against coronavirus disease 2019><immunity to COVID-19><immunity to COVID19><immunity to SARS-CoV-2><immunity to Severe acute respiratory syndrome coronavirus 2><immunity to coronavirus disease 2019><immunization strategy><infection risk><interdisciplinary approach><mRNA><multidisciplinary approach><nCoV2><pandemic><pandemic disease><prototype><receptor binding><receptor bound><seventeen year old><seventeen years of age><severe acute respiratory syndrome coronavirus 2 antigen><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><vaccination strategy><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><variants of concern><viral infection><virus infection><virus-induced disease><youngster>